Profile data is unavailable for this security.
About the company
Dishman Carbogen Amcis Limited is engaged in contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules, such as specialty chemicals, vitamins and chemicals, and disinfectants. The Company's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The Company assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The Company has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The Company's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.
- Revenue in INR (TTM)23.63bn
- Net income in INR-36.60m
- Incorporated2007
- Employees1.17k
- LocationDishman Carbogen Amcis LtdDishman Corporate HouseIscon-Bopal Road, AmbliAHMEDABAD 380058IndiaIND
- Phone+91 2 717420102
- Fax+91 7 926420198
- Websitehttps://www.carbogen-amcis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Morepen Laboratories Ltd | 14.22bn | 427.58m | 13.19bn | 2.38k | 30.84 | -- | 18.68 | 0.9274 | 0.8367 | 0.8367 | 27.43 | -- | -- | -- | -- | 5,980,358.00 | -- | 8.25 | -- | 17.08 | 32.72 | 33.95 | 3.01 | 5.86 | -- | 24.75 | -- | 0.00 | 30.20 | 21.04 | 4.73 | 33.89 | 46.89 | -- |
| Novartis India Ltd | 4.01bn | 549.70m | 13.92bn | 81.00 | 25.32 | -- | 23.10 | 3.47 | 22.26 | 22.26 | 162.31 | -- | -- | -- | -- | 49,497,530.00 | -- | 3.13 | -- | 3.97 | 48.86 | 57.42 | 13.71 | 7.18 | -- | 31.51 | -- | 75.56 | 4.86 | -9.43 | -117.80 | -- | -29.15 | 0.00 |
| TTK Health Care Ltd | 7.04bn | 284.73m | 14.67bn | 2.59k | 51.49 | -- | 34.99 | 2.08 | 20.16 | 448.26 | 498.06 | -- | -- | -- | -- | 2,718,869.00 | -- | 5.08 | -- | 8.37 | 51.26 | 56.70 | 4.05 | 3.76 | -- | 1.52 | -- | 34.31 | 25.88 | 2.57 | -49.68 | -0.2463 | 3.72 | 14.87 |
| Alembic Ltd | 1.08bn | 1.43bn | 15.16bn | 305.00 | 10.57 | -- | 17.43 | 13.99 | 5.59 | 5.59 | 4.22 | -- | -- | -- | -- | 3,552,853.00 | -- | 3.40 | -- | 3.52 | 68.66 | 50.21 | 74.35 | 58.12 | -- | 53.28 | -- | 6.08 | 6.39 | -11.87 | -35.23 | 8.84 | 20.12 | 55.18 |
| Supriya Lifescience Ltd | 5.07bn | 978.40m | 15.35bn | -- | 15.68 | -- | 14.06 | 3.03 | 12.16 | 12.16 | 63.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 59.74 | -- | 19.30 | -- | -- | 6.36 | -- | -- | 37.54 | -- | 22.60 | -- | -- | -- |
| Orchid Pharma Ltd | 6.34bn | -174.88m | 15.64bn | 1.80k | -- | -- | 25.08 | 2.47 | -4.27 | -4.74 | 154.96 | -- | -- | -- | -- | -- | -- | -4.56 | -- | -9.13 | 42.02 | 50.02 | -1.87 | -18.16 | -- | -0.0711 | -- | -- | 24.33 | -7.07 | 36.56 | -- | 10.67 | -- |
| Amrutanjan Health Care Ltd | 3.86bn | 418.46m | 16.81bn | 647.00 | 40.27 | -- | 35.80 | 4.36 | 14.30 | 14.30 | 131.85 | -- | -- | -- | -- | 5,964,019.00 | -- | 18.30 | -- | 22.82 | 53.11 | 54.97 | 10.84 | 13.46 | -- | 118.34 | -- | 21.83 | 21.93 | 13.32 | 9.80 | 23.79 | 43.89 | 33.13 |
| SeQuent Scientific Ltd | 14.38bn | -189.19m | 18.04bn | 1.96k | -- | -- | 52.87 | 1.25 | -0.768 | -0.768 | 57.56 | -- | -- | -- | -- | 7,343,974.00 | -- | 4.11 | -- | 6.41 | 42.22 | 43.83 | -1.38 | 5.11 | -- | 0.1454 | -- | 11.31 | 3.76 | 15.44 | -57.09 | -- | -16.24 | -- |
| Gufic BioSciences Ltd | 6.80bn | 818.63m | 18.07bn | 1.38k | 22.07 | -- | 18.10 | 2.66 | 8.45 | 8.45 | 70.14 | -- | -- | -- | -- | 4,918,800.00 | -- | 12.07 | -- | 26.78 | 52.82 | 44.45 | 12.04 | 8.73 | -- | 19.67 | -- | 1.54 | 59.76 | 24.51 | 116.68 | 60.42 | 84.54 | 14.87 |
| Dishman Carbogen Amcis Ltd | 23.63bn | -36.60m | 19.56bn | 1.17k | -- | -- | 6.86 | 0.8276 | -0.228 | -0.228 | 151.42 | -- | -- | -- | -- | 20,234,160.00 | -- | 0.9727 | -- | 1.17 | 79.70 | 74.41 | -0.1549 | 3.82 | -- | 0.509 | -- | 103.41 | 11.96 | 4.55 | 110.91 | -34.15 | 25.67 | -- |
| Shilpa Medicare Ltd | 11.27bn | 51.15m | 19.86bn | 2.73k | 379.01 | -- | 20.10 | 1.76 | 0.6038 | 0.6038 | 130.57 | -- | -- | -- | -- | 4,127,259.00 | -- | 5.79 | -- | 7.18 | 61.01 | 59.95 | 0.5932 | 12.81 | -- | 0.8471 | -- | 7.67 | 27.12 | 7.88 | -58.95 | -10.83 | 23.16 | 12.89 |
| Unichem Laboratories Limited | 13.11bn | -864.90m | 20.40bn | 3.17k | -- | -- | 99.13 | 1.56 | -12.41 | -12.41 | 185.65 | -- | -- | -- | -- | 4,139,174.00 | -- | -1.01 | -- | -1.21 | 63.70 | 56.52 | -6.60 | -2.70 | -- | -7.31 | -- | -- | 2.81 | 12.69 | -3.68 | -- | -3.25 | 5.92 |
| Wockhardt Ltd | 26.28bn | -6.10bn | 22.18bn | 2.96k | -- | -- | -- | 0.844 | -45.48 | -45.48 | 189.17 | -- | -- | -- | -- | 8,870,898.00 | -- | -4.12 | -- | -6.96 | 58.91 | 53.00 | -26.46 | -10.27 | -- | -0.6223 | -- | -- | 19.26 | -4.26 | 18.47 | -- | -12.38 | -- |
| Neuland Laboratories Ltd. | 10.40bn | 1.01bn | 23.15bn | 1.52k | 22.97 | -- | 15.20 | 2.23 | 78.52 | 78.52 | 810.59 | -- | -- | -- | -- | 6,837,593.00 | -- | 3.61 | -- | 5.12 | 46.63 | 41.56 | 9.69 | 5.52 | -- | 12.29 | -- | 8.12 | 1.51 | 10.11 | -20.85 | 6.37 | 18.45 | -- |
| Aarti Pharmalabs Ltd | -100.00bn | -100.00bn | 25.00bn | -- | -- | 1.63 | -- | -- | -- | -- | -- | 169.74 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.9527 | -- | 0.1633 | -- | -- | -- | 2,657,765.00 | -- | -- | -- |
| Strides Pharma Science Ltd | 35.68bn | -1.82bn | 25.86bn | 2.35k | -- | -- | 47.15 | 0.7249 | -20.26 | -18.20 | 396.69 | -- | -- | -- | -- | 15,215,500.00 | -- | -0.0665 | -- | -0.1078 | 53.65 | 49.14 | -5.27 | -0.1666 | -- | 0.1015 | -- | -- | -7.41 | 2.19 | -280.83 | -- | -26.80 | -- |
Data as of Mar 31 2023. Currency figures normalised to Dishman Carbogen Amcis Ltd's reporting currency: Indian Rupee INR
6.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HBM Partners AG (Investment Management)as of 31 Dec 2022 | 5.56m | 3.55% |
| HSBC Asset Management (India) Pvt Ltd.as of 28 Feb 2023 | 2.38m | 1.52% |
| ICICI Prudential Asset Management Co. Ltd.as of 28 Feb 2023 | 1.25m | 0.80% |
| Dimensional Fund Advisors LPas of 02 Mar 2023 | 1.19m | 0.76% |
| SSgA Funds Management, Inc.as of 02 Mar 2023 | 202.07k | 0.13% |
| Dimensional Fund Advisors Ltd.as of 02 Mar 2023 | 51.87k | 0.03% |
| American Century Investment Management, Inc.as of 02 Mar 2023 | 37.73k | 0.02% |
| DFA Australia Ltd.as of 31 Jan 2023 | 4.15k | 0.00% |
| Motilal Oswal Asset Management Co. Ltd.as of 28 Feb 2023 | 619.00 | 0.00% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 28 Feb 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2022 - 23 Mar 2023Source: FactSet Research Systems Inc.
